Summary of our Last Pitch Event on 2nd July 2024
On July 2nd MedCity hosted its latest Investment Hub Pitch event at Potter Clarkson’s offices in Holborn, showcasing 6 of the most innovative and high-growth potential companies in the London Life Sciences ecosystem.
Companies who pitched: (scroll down for a short bio of each spinoff)
- Upfront Diagnostics
- Exactmer
- Combat Medical
- Korecyte
- QV Bioelectronics
- LabCycle
We were delighted to host this pitch event in the London offices of Potter Clarkson, an IP specialist legal firm who have helped and advised a great number of companies in our network over the years. As the event began and attendees started to arrive, investors took the opportunity to speak with our six pitching companies, as well as with four additional pitch applicants who were invited to attend having scored highly in the pitch review process. With a dedicated audience space set up for attendees, the pitches soon commenced, with each company being given five minutes to deliver their pitch followed by a three minute Q&A, providing a great opportunity to build additional depth to their pitch.
The breadth of innovation showcased was impressive, with the companies being drawn from a broad range of subsectors. Investors from the MedCity early-stage investor network as well as some investors whom were attending a MedCity pitch event for the first time, commented on the strength of the pitches.
The short networking session afterwards provided an opportunity for the investors and pitching companies to get to learn about each other in even greater depth. The networking also brought in the four additional companies in attendance, Potter Clarkson representatives and the MedCity team, contributing to a rich variety of conversations and connections being formed in the room.
How Can Investors Be Part of Our Next Event?
We are always bringing new companies into our network, resulting in a broad variety and ever changing composition of companies being showcased at our pitch events. We typically run two Investment Hub Pitch callouts per year, and will always publicise this to our investor networks as soon as a date and location are set.
If you’re an early-stage Angel investor who would be interested in joining for our next pitch, please contact pranethabaskaran@londonandpartners.com for more details.
Pitching Company Bios
Upfront (Diagnostic)
‘LVONE’ is a rapid blood test that can detect large vessel occlusions (LVO) in the ambulance. 20M stroke cases worldwide and LVO strokes are responsible for 95% of disabilities and deaths. They have raised £3.8M and are looking to raise £3M. They have a few certifications and patents and have already signed a contract with NHS and are looking for funding for regulation and trials.
Exactmer (Advance Therapies)
Liquid phase manufacture of exact polymers. Oligonucleotide therapies are a next generation of advanced therapeutics treating a wide range of diseases. Exactmer completed an R&D Process Development Project for a Large Pharma customer and has a Licence Agreement in place with AstraZeneca, Novartis, Alnylam and CPI for the development of Nanostar Sieving for oligonucleotide manufacturing. Their ask is 10M and they own 5 Patents.
Combat Medical (Advance Therapies)
World leading hyperthermic technology set to transform cancer treatment. Combat Medical’s Patented Market Ready Device Targets tumors with hyperthermic drug delivery. They have raised £13.7 M and are looking to raise £2M to support FDA reviewed HIVEC® Heat Trial launching in 25 NHS hospitals.
Korecyte (Advance Therapies)
HypoxiCAR platform technology – Next-generation CART-based immunotherapy. Any CART construct or cell type is amenable to HypoxiCAR and for various disease areas (oncology, ischemic diseases). They have raised £2M and are looking to raise £3M for first in human studies.
QVBioelectronics (MedTech)
QV offers a step change in the treatment of brain cancer with a first-in-class implantable bioelectronic device. GRACE: World’s first implanted electric field therapy. They have raised £4.8M and are looking to raise £4.5M for design freeze and validation and commence Phase I/II trials.
LabCycle (Sustainability)
Pioneering a circular economy for lab plastics. Scalable modular decontamination facility, patent protected and ready to scale. They are seeking £1.5M for operations.